Company intelligence / Profile preview

BioCrag

Durham, North Carolina, USA

Ownership: Private
Employees: ~703
Development stage: Other

Overview

BioCryst is a commercial-stage biotech company specializing in oral small-molecule and protein therapeutics for rare diseases. Its lead product ORLADEYO (berotralstat) is approved for hereditary angioedema; peramivir is approved for influenza. The company also has antiviral candidates like galidesivir in development. Recent clinical milestones include FDA acceptance of ORLADEYO's pediatric use NDA in 2025.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Small moleculeProtein
Industry: Biotech

Partnerships

U.S. government agencies including NIAID and BARDA for antiviral developmentShionogi & Co. licensed peramivir in Japan.

Beyond the preview

Go deeper on BioCrag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCrag.

Explore the full profile